When medication levels remain steady, patients may experience more consistent appetite control and fewer fluctuations in how they feel physically
In fact, it can reduce cardiovascular risks in people with diabetes, insulin resistance, obesity, or heaviness with comorbid conditions
It belongs to a novel class of drugs known as triple agonists, meaning it simultaneously activates three hormone receptors: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor
The two compounds activate distinct somatotroph receptors (GHRH-R and GHS-R1a), producing additive GH release in published rodent and primate models without the cortisol or prolactin spillover seen with earlier GHRPs, because they couple to different intracellular signalling cascades
Multiple sclerosis progression: time for a new mechanism-driven framework